Insider trade

Officer sold ~$2.27M of GILD shares in the open market

Traded Aug 17, 2026 · Filed Aug 18, 2026

~$2.27M
Reported value · 17K sh @ $137.365: 130K
Holds after · shares reported: +6.2%
stock since the trade · S&P 500 -1.1%, $138.92 → $147.50 on Oct 1

Why it stands out

Gilead Sciences's Chief Comm & Corp Aff Officer sold $2.27M of Gilead Sciences shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 17, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 18, 2026

Officer$1M+Pre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$2,270,643

Shares × reported transaction price

Timing vs results

13 days after results of Aug 4, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $138.92 on Aug 17, 2026, 26% above its 52-week low and 11% below its high, after a 7% rise over the previous 30 trading days

52-week range $110.56 (Oct 2, 2025) to $155.80 (Feb 11, 2026), 63% of the way up, from 251 adjusted closes. 30 trading days earlier: $129.61 on Jul 6, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Bixlenvo Sunlenca Starter Pack (Copackaged) on Aug 27, 2026, 10 days after this trade.

New drug application approved. Active ingredient: Bictegravir Sodium, Lenacapavir Sodium, Lenacapavir Sodium. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+0.3%	-0.4%	+0.7%
30 days	+1.7%	-1.0%	+2.7%

Past results only. Not a forecast.

Source receipt

Record ID: 0001782135-26-000028
Filed / recorded: Aug 18, 2026, 10:54 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: GILEAD SCIENCES, INC.
Issuer CIK: 882095
Ticker: GILD
Reporting person: Johanna Mercier
Relationship: Officer
Officer title: Chief Comm & Corp Aff Officer
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Aug 17, 2026
Transaction code: S
Shares / units: 16,530
Price per share: $137.365
Acquired / disposed: Disposed (D)
Shares owned after: 129,704
Ownership form: Direct
Amendment: No

Footnotes from the filing

The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
Sale prices for the transactions reported range from $136.74 to $137.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Around the same time

CFO sold ~$436K of Gilead Sciences

Scheduled in advance3w ago

Officer sold ~$230K of Gilead Sciences

Scheduled in advance3w ago

Officer sold ~$116K of Gilead Sciences

Scheduled in advance3w ago